Aripiprazole-Induced Parkinsonism and Its Association With Dopamine and Serotonin Receptor Polymorphisms

López-Torres, Enrique; Salomón, Jesús Rafael Del Castillo; Vicario, Francis; Peñas-Lledó, Eva; Dorado, Pedro; LLerena, Adrián

doi:10.1097/jcp.0b013e318172757f

Cited by 9 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the decreased monoamine uptake in the thalamus shown in this study could be associated with increased susceptibility to DIP upon exposure to an offending drug. Previous studies of the genetic polymorphism of serotonin receptors and transporters provide evidence of the development of DIP and extrapyramidal symptoms in a DIP patient and schizophrenic patients 11 , 12 . Additional explanation is that offending drugs such as selective serotonin reuptake inhibitors and many antipsychotics potentially block serotonin transporters in the thalamus 8 .…”

Section: Discussionmentioning

confidence: 99%

Decreased thalamic monoamine availability in drug-induced parkinsonism

Yoo

Lyoo

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Drug-induced parkinsonism (DIP) is caused by a dopamine receptor blockade and is a major cause of misleading diagnosis of Parkinson’s disease (PD). Striatal dopamine activity has been investigated widely in DIP; however, most studies with dopamine transporter imaging have focused on the clinical characteristics and prognosis. This study investigated differences in striatal subregional monoamine availability among patients with DIP, normal controls, and patients with early PD. Thirty-five DIP patients, the same number of age-matched PD patients, and 46 healthy controls were selected for this study. Parkinsonian motor status was examined. Brain magnetic resonance imaging and positron emission tomography with 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane were performed, and the regional standardized uptake values were analyzed with a volume-of-interest template and compared among the groups. The groups were evenly matched for age, but there were numerically more females in the DIP group. Parkinsonian motor symptoms were similar in the DIP and PD groups. Monoamine availability in the thalamus of the DIP group was lower than that of the normal controls and similar to that of the PD group. In other subregions (putamen, globus pallidus, and ventral striatum), monoamine availability in the DIP group and normal controls did not differ and was higher than that in the PD group. This difference compared to healthy subject suggests that low monoamine availability in the thalamus could be an imaging biomarker of DIP.

show abstract

Section: Discussionmentioning

confidence: 99%

Decreased thalamic monoamine availability in drug-induced parkinsonism

Yoo

Lyoo

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Therefore, the decreased monoamine uptake in the thalamus shown in this study could be associated with increased susceptibility to DIP upon exposure to an offending drug. Previous studies of the genetic polymorphism of serotonin receptors and transporters provide evidence of the development of DIP and extrapyramidal symptoms in a DIP patient and schizophrenic patients [11,12]. Additional explanation is that offending drugs such as selective serotonin reuptake inhibitors and many antipsychotics potentially block serotonin transporters in the thalamus [8].…”

Section: Discussionmentioning

confidence: 99%

Decreased Thalamic Monoamine Availability in Drug-Induced Parkinsonism

Yoo

Lyoo

et al. 2021

Preprint

View full text Add to dashboard Cite

Drug-induced parkinsonism (DIP) is caused by a dopamine receptor blockade and is a major cause of misleading diagnosis of Parkinson’s disease (PD). Striatal dopamine activity has been investigated widely in DIP; however, most studies with dopamine transporter imaging have focused on the clinical characteristics and prognosis. This study investigated differences in striatal subregional monoamine availability among patients with DIP, normal controls, and patients with early PD. Thirty-five DIP patients, the same number of age-matched PD patients, and 46 healthy controls were selected for this study. Parkinsonian motor status was examined. Brain magnetic resonance imaging and positron emission tomography with 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane were performed, and the regional standardized uptake values were analyzed with a volume-of-interest template and compared among the groups. Females were more predominant in the DIP group than in the PD group. Parkinsonian motor symptoms were similar in the DIP and PD groups. Monoamine availability in the thalamus of the DIP group was lower than that of the normal controls and similar to that of the PD group. In other subregions (putamen, globus pallidus, and ventral striatum), monoamine availability in the DIP group and normal controls did not differ and was higher than that in the PD group. These findings suggest that low monoamine availability in the thalamus could be an imaging biomarker of DIP.

show abstract

“…41,55 Despite its good overall safety profi le, clinical monitoring of cardiovascular, metabolic, and neurological side effects is still indicated in patients treated with aripiprazole. Rare case reports of keto-acidosis, 58 elevation of triglycerides, 59 neuroleptic malignant syndrome, 60 and parkinsonism 61 have been published, although not necessarily in bipolar disorder.…”

Section: Safety and Tolerabiltymentioning

confidence: 99%

Pharmacotherapy of Bipolar I Disorder: Focus on Aripiprazole

Bastiaens

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Bipolar disorder is a common and complex condition, starting early in life and continuing throughout the life cycle. Most people suffering from bipolar disorder manifest other problems as well, including metabolic disturbances, cardiovascular disease, anxiety disorders, substance use disorders, attention defi cit hyperactivity disorder, and borderline personality disorder, among others. The treatment of bipolar disorder needs to be conceptualized within this context of early onset, chronic course, and signifi cant co-morbidity. Because of its unique mode of action, its effi cacy and its good tolerability profi le, aripiprazole is well placed among the different treatment options to benefi t the patient with bipolar disorder. This article will focus on aripiprazole's pharmacology, effi cacy, effectiveness, and tolerability from a clinical perspective, while considering the complexities of bipolar disorder.

show abstract

Aripiprazole-Induced Parkinsonism and Its Association With Dopamine and Serotonin Receptor Polymorphisms

Abstract: P 0.0267 <0.0001 0.0083 0.0196 0.0139The figures represent the correlation coefficients and the P values for each comparison.

Cited by 9 publications

References 11 publications

Decreased thalamic monoamine availability in drug-induced parkinsonism

Decreased thalamic monoamine availability in drug-induced parkinsonism

Decreased Thalamic Monoamine Availability in Drug-Induced Parkinsonism

Pharmacotherapy of Bipolar I Disorder: Focus on Aripiprazole

Contact Info

Product

Resources

About